From Asia to Europe, NeoBards continues to bring rich and diverse gaming experience to players around the globe.

 

NeoBards Entertainment Ltd. was founded in 2017 by industry elites from all around the world, focusing on combining international resources to develop high-quality games. For years, NeoBards have worked together with renowned game companies such as CAPCOM, SQUARE ENIX, and KONAMI, to release a series of high-profile and well-known IP games, including Mega Man Battle Network Legacy Collection, Resident Evil: Resistance, Marvel’s Avengers, and SILENT HILL f, which is currently in development.

 

Both studios in Taipei and Suzhou have been operating successfully. As the number and scale of our game development continue to grow, establishing a new studio in Europe has long been in the planning. Finally, NeoBards decided to set foot in Breda, a college town in the Southern Netherlands. Breda University of Applied Sciences, a top university in Breda, focuses on the cultivation of experts in digital science and technology, with in-depth research programs in the fields of gaming and AI. This advantage will provide NeoBards with access to excellent local talents, as well as experienced and skillful developers from all over Europe. The new studio also has exciting game projects on the way.

 

 

About NeoBards
NeoBards Entertainment Ltd. is an independent game developer founded in 2017 by a group of likeminded industry veterans boasting over 20 years of game development experience, with headquarters in Hong Kong and studios in Taipei, Suzhou and Breda, the Netherlands. Recent works include co-dev projects with Capcom on Mega Man Battle Network Legacy Collection, Resident Evil: Resistance, Resident Evil Re:Verse, Devil May Cry HD Collection, Resident Evil Origins Collection, Onimusha: Warlords; and character skill design/ implementation for Square Enix’s Marvel’s Avengers. There are 3 games currently in development. Apart from SILENT HILL f, a co-dev project with KONAMI, two other games are yet to be announced.